Based on this rationale, the phase III KEYNOTE-811 study compared first-line pembro or placebo plus trastuzumab plus chemotherapy (fluoropyrimidine plus platinum) in 698 patients with advanced or metastatic HER-2 positive GC (n = 466) or GEJ cancer (n = 232). Here, ERBB2 is linked to gastric cancer.